NCT06132841 - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2023

Primary Completion Date

March 4, 2026

Study Completion Date

March 23, 2026

Conditions

Healthy Participants

Interventions

DRUG

AZD6234

Participants will receive repeated doses of AZD6234 as a solution via SC

DRUG

Placebo

Participants will receive matching volumes of the placebo as a solution via SC

Trial Locations (3)

Research Site, Brooklyn

Research Site, Glendale

Research Site, Osaka